KRAS and colorectal carcinoma: The phase I clinical trial of berzosertib in monotherapy or in association with carboplatin included 11 patients with KRAS and BRAF wild type advanced CRC harboring ATM loss and an AT-rich interactive domain 1A (ARID1A) mutation (NCT02157792).